2 5 Y E A R S AT B AY L O R C O L L E G E O F M E D I C I N E
little more than Tech transfer got its
two decades ago, start at BCM a quarter
Baylor College of Medicine century ago after federal
pathologist Dr. David legislation passed that
Yawn, along with former enabled universities to
BCM surgery machine shop have ownership of inven
manager Lou Feldman, tions—rather than the
developed an innovative government—and work
device that improved blood directly with companies
processing during surgeries on commercialization
that involved extreme blood and licensing of those
loss, like the aortic aneurysm discoveries.
procedure. The technology transfer,
That device—known licensing and startup com
as the Baylor BRAT— pany functions were orginally
was the basis for the first part of BCM Technologies
Baylor Licensing Group
company resulting from the (BCMT). Those functions
technology transfer process were separated about 10
at Baylor College of Medicine. years ago. BLG is responsible for the technology transfer
Technology transfer at BCM is now celebrating and licensing services, and BCMT provides the startup
its 25th anniversary, and since that first product, many support services.
more innovations by Baylor doctors and researchers Some faculty expressed hesitation at first about
have been licensed and introduced into the market. the idea of technology transfer, Schaefer noted, but
In fact, there are more than 200 diagnostic, clinical over time have embraced the concept of technology
and research products on the market based on Baylor commercialization and the benefits it provides. Now,
technology, according to Lynne Schaefer, director of continued on page 2
the Baylor Licensing Group (BLG).
Background and function Technology Transfer QUICK FACTS
BLG’s function is to transfer research results and
discoveries developed by Baylor College of Medicine • More than 500 active license agreements
faculty to the marketplace for the benefit of the public. • 1,800plus invention disclosures received from
This technology transfer process also generates a BCM faculty
financial return for the faculty and to the college. The • More than 200 products on the market based on
college’s portion is used to support its research mission. Baylor technology
“There has been a clear benefit to so many,” • $100 million gross income since 1988 from licensing
Schaefer said. “Industry and the public benefit from the – $13.1 million to Baylor Licensing Group office
creation of new products, whether in the health care – $3.6 million to legal reimbursement
field or research market. Individual patients certainly – $26.3 million to inventors
benefit from the new treatments that are developed – $18.9 million to departments
from Baylor technology. In addition, there is a positive – $22.4 retained by the college to support research
economic impact when new, local companies are formed – $15.4 million shared with funding agencies and
based on Baylor inventions.” institutions
continued from page 1
the services of the BLG are even used as a recruiting tool that, more than $26 million went to inventors, almost
when hiring new faculty. $19 million to departments and more than $22 million
The office handles the technology transfer process was retained by the college to support BCM’s research
from the very start, when a faculty member reports he endeavors.
or she has a new technology that may have commercial Income from technology transfer is used in a variety
potential. A representative from the BLG evaluates the of ways in the department of molecular and cellular
commercial viability, patentability, identifies potential biology, O’Malley said.
companies that would be interested in licensing the “In our department, that money is used for faculty
technology, negotiates the license terms, drafts the license needs that are not provided for in the yearly budget,”
agreement and coordinates legal review and approval of O’Malley said. It might provide for things like common
the agreement. The office also distributes license income equipment used by faculty, funding for service contracts,
and monitors licensee compliance. or to give financial assistance to faculty who are awaiting
Staff in the Baylor Licensing Group respond to grant funds.
inquires from BCM faculty but they also work on an
outreach basis by meeting oneonone with faculty,
Public health impact
attending department seminars, talking to chairs and mak The clear winners are the patients and the public who
ing presentations at faculty meetings, where they provide benefit from the technologies on the market.
an overview of the office and its services and benefits. Dr. Yawn’s BRAT device is an example of that. It was
“Faculty are able to see their idea move forward and developed with Dr. Stanley Crawford, a Baylor College
develop into a new technology or venture,” Schaefer said. of Medicine surgeon who pioneered surgical procedures
Dr. Rabih Darouiche, professor of physical medicine for complex aortic diseases. The BRAT—or Baylor Rapid
and rehabilitation at Baylor College of Medicine, has 13 Autologous Transfusion System—recycles a patient’s
patents for antimicrobial coated devices that are designed washed red blood cells during surgery, reducing the
to reduce infection, so he has a lot of experience working amount of blood and blood products needed during aortic
with the Baylor Licensing Group. aneurysm and other arterial surgeries. Because of this
“I have worked with the office for about two decades, technology, patients spend less time in the operating room.
and they have always been extremely suppor tive,” More recent examples include the antimicrobial
Darouiche said. “Some investigators underestimate the coating technologies for catheters and other medical
complexity of this process, but it’s much more involved devices developed by Dr. Darouiche and his colleague at
than they may realize. That’s why it’s so important to the MD Anderson Cancer Center.
have the services of the Baylor Licensing Group.” This coating reduces hospitalacquired infections
that can occur with the use of central venous catheters
Financial benefit and other medical devices. According to Infection
Dr. Bert O’Malley, professor of Control Today, the average cost of each
molecular and cellular biology and chair infection related to invasive medical
of the department, echoes that sentiment. devices varies from $34,000 to $56,000;
Faculty in basic sciences don’t have the these infections incur an annual financial
time or the resources for technology burden up to $2.3 billion to the
transfer and licensing. The college agrees, American health care system.
noted Schaefer. It is BCM policy that the
tech transfer process is the responsibility Research arena
of BLG, not the investigators. “Often people forget about the
O’Malley is also familiar with the research side, but we have licensed many
financial benefits of the Baylor Licensing technologies in this area as well,” Schaefer
Group. said. “For example, we have licensed
Faculty members receive 50 percent of many different animal models for use in
the net income received from an invention. research in prostate and other cancers,
Dr. Bert O’Malley
The remaining 50 percent is split between neurologic disease and other diseases.”
the department in which the faculty Research reagents like cell lines and
member works and the college. antibodies have also been licensed. The Baylor Licensing
Over the last 25 years, technologies licensed by BLG Group has even licensed educational tools, like videos
have generated over $100 million of gross income. Of on smoking cessation, diabetes management and other
important health topics that are of interest to groups such they were able to develop something that has helped
as the American Diabetes Association. people and benefits the public. It’s certainly a good thing
“There are so many tangible and intangible benefits for the college to be associated with these new inventions
of what we do,” Schaefer said. “I think one clear thing is and discoveries that have such an impact on public
the personal satisfaction and reward faculty get in knowing health.” u
Reducing Hospital-acquired “We started modifying the surface of a variety of
devices with antimicrobials and antibiofilm agents as
Infections well as a combination of agents in an effort to prevent
bacterial colonization of the devices and consequently
The issue of hospitalacquired infections is a serious one clinical infection,” he said. “The highest rate of infection
for the patients who develop them and generally is with catheters, which is
for the public health system as a whole. why we started our work initially with
According to the CDC, there are catheters.”
2 million cases of health care acquired Catheters are more prone to
infections annually, and half of those infection than fully implanted devices, he
are associated with medical devices, explained, because they are introduced
including catheters. But antiinfective through the skin, and bacteria from
coatings for medical devices have been the patient’s skin or from health care
shown to reduce infection, and could providers can make its way more easily
lead to lives saved and significant cost into the catheter than it does into
savings to the health care system. surgically implantable devices.
Dr. Rabih Darouiche, professor of A single episode of catheter related
physical medicine and rehabilitation septicemia can cost up to $28,000 to
at BCM, and his colleague at MD treat and result in an extra six and half
Anderson Cancer Center, Dr. Issam Dr. Rabih Darouiche
days in the hospital, Darouiche said.
Raad, started working on these Clinical trials have shown that the
antimicrobial coatings almost two decades ago. They vascular catheters developed at Baylor and MD Anderson
have worked with BCM’s technology transfer office, the are more clinically protective against infection than
Baylor Licensing Group, on obtaining patents, licenses unimpregnated catheters. What’s more, the researchers
and getting the products on the market. demonstrated that catheters coated with minocycline and
“Although there has been a lot of progress in terms rifampin are more protective than catheters coated with
of diagnosis and treatment of device related infections, for chlorhexidine and sulfadiazine, two other types of anti
a long time there wasn’t as much information regarding infective agents. These findings were published in the
optimum prevention of infection of devices,” Darouiche New England Journal of Medicine.
said. “This is what prompted our work on prevention of Currently under development are other devices
device related infections almost 20 years ago.” such as an antimicrobial impregnated hernia mesh and
Darouiche is an inventor on 13 patents for anti orthopedic implants. Darouiche’s research follows the
microbial coated devices and developed 10 FDA translational model—starting from the bench and then
approved devices. The devices are coated with different working with animal models and finally clinical trials.
types of antiinfective agents, depending on the surface of Darouiche described the Baylor Licensing Group as
the device. very supportive and said it would really be too much for
These include three different types of vascular an investigator to try to tackle the technology transfer
catheters as well as a bladder catheter and a ventricular process on his or her own.
catheter. The five others available to patients are surgically “Even if you are lucky enough to get a patent,
implanted devices with antimicrobial coating, including that does not mean your invention will make its way to
a hernia mesh, penile implants, urethral slings, artificial market and actually sell. You could end up losing money,
sphincters and an envelope around pacemakers and so that’s one reason the knowledge and resources of the
defibrillators. Baylor Licensing Group are so important.” u
Making a Vaccine for characterize the viral genome and identify these viruses
Intestinal Flu as noroviruses, a new genus of viruses within a family of
viruses called caliciviruses.
“We’re not quite finished yet but it is exciting to have Further basic work in the laboratory led to the
played a role in the making of the first candidate norovirus unexpected discovery that expression of the capsid
vaccine,” said Dr. Mary Estes, professor of proteins of Norwalk virus (the first characterized
molecular virology and microbiology. norovirus) in insect cells results in self
The vaccine’s story started in 1984, assembly of Norwalk viruslike particles.
when Dr. David Graham, professor Suddenly millions of particles were
of medicine, and Estes decided to try available, making the viruslike particles
and characterize the virus thought to a candidate vaccine as well as a tool to
cause most outbreaks of gastroenteritis develop new diagnostic reagents and
(“stomach flu”). The virus could not be assays. A patent application was filed on
grown in the laboratory, but investigators this technical advance.
at the National Institutes of Health had Preclinical studies in mice showed
seen viral particles. Volunteers could be that the viruslike particles were
infected with this virus. immunogenic or sparked an immune
However, among the many mysteries response when given by various routes
surrounding the virus was its very identity. (intramuscularly, intranasal, orally).
What information did the genome of the Dr. Mary Estes
virus harbor that might explain how it Studies in people
causes disease? In 1995, Graham, Opekun and Dr.
Mark Gilger, professor of pediatrics, demonstrated that
Previous work with virus-like particles the particles were immunogenic when given by mouth
Estes had previously developed molecular methods to volunteers, but they still needed to prove the illness
to study rotavirus, the most important cause of life protectiveproperties of
threatening diarrhea in young children, and she had the candidate vaccine.
produced a candidate recombinant rotavirus viruslike The technology was
particle (VLP) vaccine. With that experience to build on, licensed to LigoCyte
the team took on this new, multifaceted challenge. Pharmaceuticals in
Dr. Graham and Antone Opekun, P.A., assistant Bozeman, Montana.
professor of medicine, set up a challenge model, infecting LigoCyte has moved
volunteers and then following the natural course of forward to sponsor
their disease in BCM’s federally funded General Clinical the ongoing phase I/
Research Center. This II trial that is being
enabled them to not conducted at four sites
only understand the in the United States,
natural history of the including at BCM
clinical disease but to under the direction
produce virus as well. of Dr. Robert Atmar, Dr. Mark Gilger
Using virus ob professor of medicine.
tained from the stools Twentyfive years
of the volunteers who have passed between the initial challenge studies at BCM
had been infected, and the current studies, which will determine later this
Estes and postdoc year whether intranasal immunization with viruslike
toral trainee Dr. Xi particles can induce protective immunity in people.
Jiang, used their Although it may take several additional years before the
molecular expertise to FDA licensure of a successful vaccine, this story illustrates
clone, sequence and the power of molecular biology to lead to new discoveries
that may prevent or change disease treatment. It also is scientists and clinicians interested in research who have a
an example of the achievements that can be accomplished longstanding collaboration and translational facilities to
by effective interactions between a capable team of basic carry out projects of this nature. u
Multiplex PCR Speeds made possible by using more than one set of primers,
the short strands of known DNA that serve as the
Genetic Diagnosis starting points for copying a specific region of genetic
material. While gene chips have taken over some of the
By the late 1980s, scientists had identified the gene work begun with multiplex PCR, the method remains
associated with Duchenne muscular dystrophy, a deadly an important tool in a variety of fields.
disease that begins in early childhood and usually cuts a “There were a lot of deletions and we needed
life short before age 35. quicker methods to find them,” said Gibbs. “You could
The gene is responsible for production of a use PCR (polymerase chain reaction) to look for the
particular muscle protein called dystro deletions individually, but it made sense
phin. When parts of the gene are to direct that at different parts of the
deleted, little or no protein is made, gene simultaneously.”
resulting in muscle degeneration and PCR is, in a sense, a genetic
wasting. copying technique that allows scientists
However, such deletions occur at to take nanograms of genomic DNA
different places and in various sizes and make millions of copies of a specific
in the large gene. While scientists region of a gene. Multiplex PCR allows
could identify the various deletions them to do that for many different
in individual patients, they had to regions in the same reaction.
search one deletion at a time. It was “Running multiple PCRs at
inadequate, laborious and too slow. the same time was a novel insight,”
In the late 1980s, Dr. Richard Gibbs said. “It was also important
Gibbs, now professor of molecular and to recognize that you could use the
Dr. Richard Gibbs
human genetics at Baylor College of presence or absence of successful PCR
Medicine and director of the Baylor reaction as a sensitive detector of
Human Genome Sequencing, and his colleagues tackled genomic deletions. Bringing those two together with
the problem, developing a way to do several PCR our increasing knowledge of the fine structure of the
reactions at the same time in the same reaction tube in a gene was important. Getting the fine sequence of the
process known as multiplex PCR. In this way, they could gene was pivotal in allowing us to develop multiple
look for the presence or absence of various stretches of PCRs in a tube.”
DNA at the same time. BCM licensed the technology exclusively to
Among people key to developing this new process, Abbott in 1989. Abbott, in turn, has sublicensed the
Gibbs said, were Dr. Tom Caskey, formerly Chair of technology to approximately 20 companies that use it
genetics, former BCM technician Phi Nga Nguyen, and in a broad range of applications, including infectious
Dr. Jeffrey S. Chamberlain and Dr. Joel E. Ranier, then disease, genetic testing and forensics.
postdoctoral students. A patent was granted on this “Baylor has received significant income from
process in 1996. Abbott over the term of this agreement,” said Lynne
This technique could not only be applied to the Schaefer, director of the Baylor Licensing Group.
dystrophin gene to diagnose Duchenne muscular “They continue to pay royalties to Baylor based on our
dystrophy, but to any DNA molecule. The process is license agreement.” u
Products at a Glance
Innovator: Dr. Michael Innovator: Dr. Pui-Kwong Chan, professor of
Heggeness, professor pharmacology
and chair of ortho Product: A monoclonal antibody, AntiNucleophosmin/
pedic surgery B23 (NPM), that recognizes a major protein
Product: Intracept™ component of the nucleolus, the cellular site of
intraosseous nerve ribosome synthesis.
ablation system Licensee: Several companies that serve the research
Licensee: Relievant reagent market have been licensed.
Medsystems, Inc. Suggested uses: Detection of NPM by several widely
Suggested uses: The used laboratory techniques, including Western Blot,
intracept device is immunoprecipitation and immunofluorescence;
intended to treat back used as a nucleolus marker; also used in the
pain by selectively B23translocation assay, an assay that measures
ablating specific Dr. Michael Heggeness translocation of NPM.
nerves within the Advantages: This antibody offers a tool by which the
human vertebrae. impact of anticancer drugs on the nucleolus, a cellular
Advantages: This method offers many advantages over site where a number of anticancer drugs localize,
existing approaches for treating back pain. Requiring can be measured. The translocation of NPM from
only a small incision, it is minimally invasive which the nucleolus to the nucleoplasm can be visualized
contributes to a reduction in both surgical and by the use of the antiNPM antibody. Druginduced
recovery time. The treatment is very controlled and translocation of NPM can be used to assess the ability
specific to certain types of back pain. of certain anticancer drugs to cause cytotoxicity or
In his words: The idea arose after I discovered the apoptosis (programmed cell death) in tumor cell lines.
basivertebral nerves during a study of human vertebral In his words: As a junior faculty member, I studied
anatomy in 19951997. The idea that these nerves a major nucleolar protein, protein B23/Nucleo
may be responsible for certain kinds of human back phosmin. To do this, an antibody was needed. I
pain led me to design and, with BLG assistance, revived the clone of B23 monoclonal antibody with
obtain patent protection. The idea was then central to Dr. M. Lischwe. With this monoclonal antibody, we
the formation of Relievant Medsystems Inc., which is discovered that B23 shuttles between nucleolus and
now manufacturing and moving the product through nucleoplasm and even to cytoplasm. We called this
the FDA approval process. phenomenon “B23translocation.” One of the uses
of this phenomenon is for determining the effect of
Innovator: Dr. Vladimir Didenko, associate professor, certain anticancer drugs. The antibody also helps us
department of neurosurgery to identify the cDNA and the genomic clone of B23
Product: ApopTag® Peroxidase In Situ Oligo and their sequences. Through the years, I have been
Ligation Kit sending this antibody to scientists/colleagues all over
Licensee: Millipore Corp. the world. Thanks to the tech transfer group at BCM,
Suggested uses: Apoptosis is a mode of cell death this antibody has been licensed to several companies,
morphologically and biochemically distinct from which saves me the time of sending it.
necrosis, or nonprogrammed cell death. It is a crucial
part of the developmental process in multicellular Innovator: Dr. David Spencer, professor of
organisms, and it is thought that many cancers start immunology
when apoptosis fails and cells refuse to die off as Product: BPGMAXCD1
they should. This assay provides a more specific and Licensee: Bellicum Pharmaceuticals, Inc., a Houston
detailed detection of apoptosis in tissue sections. based cancer vaccine company.
Users include a wide range of molecular and cellular Suggested uses: The goal of this product is to harness
biologists and molecular pathologists. the power of the immune system to seek out and
Advantages: This assay is more specific than other destroy cancer cells. BPGMAXCD1 is a novel
currently used assays for apoptosis detection. dendritic cell (DC) vaccine platform currently being
tested in clinical trials for patients with metastatic
castrationresistant prostate cancer. Dendritic cells are
specialized cells in the immune system that function
to present antigens to T cells, which then act as the This has resulted in a large demand for the TSGp53
effector arm of the immune response. T cells become model by pharmaceutical companies.
activated by this process and can then act to seek out Advantages: Can assess p53 function in a whole
and destroy tumor cells that display the same antigen. organismal context. Cells derived from p53deficient
This product uses a molecule called inducible CD40 mice can be used to study effects of p53 absence on
to boost the ability of DCs to display antigens and other signaling pathways and on cellular functions.
activate T cells, producing a “turbocharged” immune These cells can be readily immortalized and
response against cancer cells. transformed.
Advantages: Permits enhanced activation of dendritic In his words: This project evolved from conversations
cells in vivo vs. traditional DCbased vaccines. The with Allan Bradley about the feasibility of knocking
same dendritic cell platform can be used for other out a tumor suppressor gene like p53. At that time,
tumors. Allan was down the hall from me and had pioneered
In his words: This project was originally the thesis the early mouse knockout technologies. I had been
project of MSTP student Brent Hanks, and was later working with Janet Butel studying p53, a prototypical
adapted for human use by postdoctoral fellow and tumor suppressor, and Allan and I agreed that p53
now instructor Natalia Lapteva. This is a longtime would be a great target for a knockout strategy. There
collaboration with Kevin Slawin, formerly of the was pretty intense competition in his field, but luckily
department of urology and now president and CEO we were the first to publish on a tumor suppressor
of Vanguard Urologic Institute in Houston. knockout mouse.
Innovator: Dr. Nancy Weigel, professor of molecular Innovator: Dr. David
and cellular biology Graham, professor
Product: AR441 monoclonal antibody of medicine –
Licensee: Several companies that serve the research gastroenterology
reagent market have been licensed. Product: BreathTek™
Suggested uses: Detection of human androgen Licensee: Meretek
receptor by immunoblotting and immunohisto Diagnostics Group
chemistry. Androgen receptors play a role in advanced of Otsuka America
prostate cancer. Pharmaceutical, Inc.
Advantages: The antibody recognizes human, but Suggested uses:
not rodent, androgen receptors. Therefore, it is very The BreathTek
sensitive and highly specific. system aids in the
In her words: I designed the peptide antigen based initial diagnosis
on the sequence of human androgen receptor. The and posttreatment Dr. David Graham
antibody was produced by the monoclonal antibody monitoring of active
core directed by Dr. Dean Edwards and the University Helicobacter pylori (H. pylori) infections in adult patients.
of Colorado Health Science Center Denver. He is now Advantages: BreathTek is a simple, noninvasive test
a Baylor faculty member. that can provide results very quickly.
In his words: H. pylori is known to cause peptic ulcers,
Innovator: Dr. Larry Donehower, professor of gastritis and gastric cancer. It was discovered in
molecular virology and microbiology 1984, by Drs. Warren and Marshall. They received
Product: TSGp53 mouse the Nobel prize for this work in 2005. Early on,
Licensee: Taconic after its discovery, there was no proof it caused any
Suggested uses: p53, a tumor suppressor protein is disease, and clinical studies were needed. To do those,
known to be mutated in many cancer types, including diagnostic tests were needed. We at Baylor developed
lung, colon and bladder cancer. This mouse, where the first accurate serologic test (HMCAP) with
the p53 gene has been knocked out, has been widely Doyle and Dolores Evans and the first noninvasive
used by researchers to investigate the role of p53, in test, the urea breath test. Those tests were critical for
protection against cancer and general p53 functions in the subsequent studies to understand the infection
an in vivo context. and to develop drugs regimes to cure the infection
In addition to this basic research use, the TSGp53 (which was critical to prove that the infection caused
mouse has been approved by the FDA as a model for those diseases). The urea breath test was developed
the standard twoyear rodent carcinogenicity bioassay with Peter Klein and the breath collection bags with
required by the FDA on all new pharmaceutical drugs. Antone Opekun and Bill Wong. u
Meet the Staff
Lynne D. Schaefer Previously, he worked as an associate investigator at St.
Director Jude Children’s Research Hospital, where he studied
Lynne has more than 25 years experience in all signal transduction pathways in rhabdomyosarcoma, a
aspects of technology transfer. She was previously with pediatric skeletal muscle tumor. He also has extensive
BCM Technologies, Inc., Baylor College of Medicine’s experience working with retroviral vectors. Michael is
technology transfer company, from its inception in active in LES and AUTM, where he served as the vice
1983 through 2000. Prior to BCMT, Lynne was a sales president for the central region and was a member of
representative for a small, specialty chemical company in the Board of Trustees, Michael received an M.B.A. in
Houston. She is active in the Association of University finance from the University of Memphis and a Ph.D. in
Technology Managers (AUTM), and a member of genetics from Texas A&M University.
the Licensing Executive Society (LES). She holds a Email: email@example.com
B.S. degree in marine biology from Roger Williams
University in Rhode Island and an M.B.A. from the Lisa Beveridge
University of Houston. Senior Licensing Manager
Her primary focus is on management, planning, Lisa joined BLG in 2001. She brings with her
and policy issues. 25 years of experience in the medical field including
Email: firstname.lastname@example.org clinical, sales, technical support, marketing, market
research and business development in various medi
Larry Hope cal companies. Lisa has authored two medical market
Technology Licensing Manager research reports for Frost & Sullivan Market Intelli
Larry joined BLG in 1999. Previously he held gence and negotiated many licensing agreements for
market research and business development positions Aventis Pharma. She is active in AUTM and LES. Lisa
at several Houstonarea biotechnology companies. has a B.S. in Medical Technology from the University
Most recently he was with the marketing department of Delaware and has done postgraduate work at Temple
of LifeCell Corp. He is a member of AUTM and LES. University and the Medical College of Pennsylvania in
Larry holds a B.S. in microbiology from Texas A&M hematology. Lisa manages the BLG Internship Program
University and an M.B.A. in finance and entrepreneur and the BLG Standard Operating Procedures.
ship from Rice University. Email: email@example.com
Terese Rakow, Ph.D. Administrative Coordinator
Senior Licensing Associate Nellie has been with Baylor College of Medicine
Terese joined BLG in 1999. She received her Ph.D. since 1998, working in a variety of administrative
in zoology and genetics from Iowa State University positions in ophthalmology and the Office of Faculty
and did her postdoctoral training at the University Affairs. Joining BLG in January 2003, Nellie has
of California – San Diego and The Scripps Research extensive experience in database management, SAP
Institute in genetics and neurobiology using the accounting systems and customer service.
nematode C. elegans. Terese is active in AUTM and Email: firstname.lastname@example.org
LES and has been the newsletter coordinator for BLG
since 2000. Nakkiah Stubblefield
Email: email@example.com Project Coordinator
Nakkiah handles all intellectual property
Michael Dilling, Ph.D. administrative matters for the group. She has been with
Senior Licensing Associate Baylor College of Medicine since December 2003.
Michael joined BLG in 2000. A Certified Licensing Nakkiah previously worked as an executive assistant for
Professional, he has negotiated and closed more than 70 the president of a dental office and has an A.A.S. degree
license/option agreements, including exclusive licenses in Computer Aided Drafting.
for therapeutics, vaccine technologies, gene therapy Email: firstname.lastname@example.org
and immunotherapy technologies and medical devices.